| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 106.4 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Hepatic transplantation is a lifesaving therapy that has been increasing over the years in Portugal. Its success is due largely in part to the use of immunosuppressants, like tacrolimus, the first-line immunosuppressant drug for people undergoing liver transplantation. It is a drug with narrow therapeutic window and great inter-individual variability. This variability is explained in part by polymorphisms of the CYP3A5 gene, which encodes the CYP3A5 metabolizing enzyme. The rs776746 polymorphism affects the CYP3A5 gene and gives rise to a non-functional metabolizing enzyme. The CYP3A5 gene is expressed in both the liver and the gut, that is, the metabolism of tacrolimus is affected by the transplanted liver (donor) genotype, as well as by the gut (receptor) genotype. The identification of polymorphisms becomes important especially in the period immediately after transplantation in order to avoid acute rejection of the organ.
Description
Keywords
Transplant Liver Polymorphism rs776746 Tacrolimus CYP3A5
Citation
Rocha, C., & Santos, M. (2018). Influence of the rs776746 CYP 3A5 gene polymorphism on response to immunosuppressant tacrolimus in patients undergoing liver transplantation: a systematic review. Proceedings of the 4th IPLeiria’s International Health Congress, Leiria.
Publisher
Springer